Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
Objective In December 2020, 2 lipid nanoparticle-formulated, nucleoside-modified messenger RNA–based vaccines received emergency use authorization by the US Food and Drug Administration, after their trials demonstrated 94% to 95% efficacy…